Tharimmune (THAR) Competitors $1.65 +0.02 (+1.23%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$1.67 +0.02 (+1.15%) As of 07/17/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. RVPH, HOTH, RLYB, QTTB, PRPH, ASBP, GELS, CASI, LPCN, and MTEXShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Reviva Pharmaceuticals (RVPH), Hoth Therapeutics (HOTH), Rallybio (RLYB), Q32 Bio (QTTB), ProPhase Labs (PRPH), Aspire Biopharma (ASBP), Gelteq (GELS), CASI Pharmaceuticals (CASI), Lipocine (LPCN), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors Reviva Pharmaceuticals Hoth Therapeutics Rallybio Q32 Bio ProPhase Labs Aspire Biopharma Gelteq CASI Pharmaceuticals Lipocine Mannatech Reviva Pharmaceuticals (NASDAQ:RVPH) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk. Is RVPH or THAR more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -302.31% Tharimmune N/A -489.33%-264.34% Do insiders and institutionals have more ownership in RVPH or THAR? 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 10.0% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer RVPH or THAR? In the previous week, Tharimmune's average media sentiment score of 1.89 beat Reviva Pharmaceuticals' score of 1.87 indicating that Tharimmune is being referred to more favorably in the news media. Company Overall Sentiment Reviva Pharmaceuticals Very Positive Tharimmune Very Positive Which has more volatility & risk, RVPH or THAR? Reviva Pharmaceuticals has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Which has higher earnings and valuation, RVPH or THAR? Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.79-0.51TharimmuneN/AN/A-$12.20M-$7.88-0.21 Do analysts rate RVPH or THAR? Reviva Pharmaceuticals presently has a consensus price target of $9.00, indicating a potential upside of 2,121.13%. Tharimmune has a consensus price target of $17.00, indicating a potential upside of 930.30%. Given Reviva Pharmaceuticals' higher possible upside, equities research analysts clearly believe Reviva Pharmaceuticals is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryReviva Pharmaceuticals beats Tharimmune on 7 of the 13 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.34M$2.94B$5.57B$9.34BDividend YieldN/A2.45%3.80%4.06%P/E Ratio-0.2120.2928.1019.86Price / SalesN/A302.32441.4199.92Price / CashN/A43.1635.8457.94Price / Book2.437.838.265.67Net Income-$12.20M-$55.11M$3.24B$257.80M7 Day Performance-4.62%3.21%1.48%1.87%1 Month Performance15.38%12.86%8.07%10.92%1 Year Performance-56.58%5.06%30.29%18.51% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune3.2052 of 5 stars$1.65+1.2%$17.00+930.3%-53.8%$4.34MN/A-0.212Positive NewsRVPHReviva Pharmaceuticals3.3873 of 5 stars$0.39+2.8%$9.00+2,225.6%-66.1%$18.58MN/A-0.495Positive NewsGap UpHOTHHoth Therapeutics3.1651 of 5 stars$1.40+7.3%$4.00+186.7%+42.6%$18.43MN/A-1.224Positive NewsRLYBRallybio2.6801 of 5 stars$0.44-13.8%$10.00+2,167.6%-67.3%$18.39M$640K-0.4140High Trading VolumeQTTBQ32 Bio2.7251 of 5 stars$1.49+7.2%$12.17+716.6%-91.5%$18.17M$1.16M-0.3039PRPHProPhase Labs0.5375 of 5 stars$0.43flatN/A-88.5%$18.03M$6.77M-0.34130Positive NewsASBPAspire BiopharmaN/A$0.36+15.1%N/AN/A$17.85MN/A0.00N/APositive NewsHigh Trading VolumeGELSGelteqN/A$1.88-1.3%N/AN/A$17.70M$100K0.00N/ANews CoverageGap DownCASICASI Pharmaceuticals4.1791 of 5 stars$1.40-0.1%$4.00+184.9%-79.5%$17.27M$28.54M-0.55180LPCNLipocine3.0569 of 5 stars$3.21+2.4%$9.00+180.0%-50.3%$17.12M$11.20M-3.1410MTEXMannatech1.2354 of 5 stars$8.82+4.8%N/A+12.3%$16.75M$117.87M-88.15250 Related Companies and Tools Related Companies Reviva Pharmaceuticals Competitors Hoth Therapeutics Competitors Rallybio Competitors Q32 Bio Competitors ProPhase Labs Competitors Aspire Biopharma Competitors Gelteq Competitors CASI Pharmaceuticals Competitors Lipocine Competitors Mannatech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
